Search
Vir Biotechnology Inc
VIRAdd to Watchlist
11.000USD
-0.300-2.65%
Close 11-02 16:00（ET）
1.86BMarket Cap
LossP/E TTM
Vir Biotechnology Inc (VIR) Stock Price Target & Forecast
Analyst Rating
Based on 9 analysts giving stock ratings to Vir Biotechnology Inc in the past month.
Buy
3 Strong Buy
6 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
21.000USD+76.03%
VIR Analyst Recommendation Trends
In the current month, VIR has received 6 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. VIR average Analyst price target in the last month is 21.000.
2026-11
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
3
3
3
3
3
3
3
3
6
7
7
7
7
7
7
7
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
9
10
10
10
10
10
10
10
VIR Analyst Rating for Peer Comparison
Updated: Nov 1, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
0
0
27
argenx SE
ARGX
10
14
3
0
0
27
Ionis Pharmaceuticals Inc
IONS
6
14
5
0
0
25
Insmed Inc
INSM
7
18
0
0
0
25
Revolution Medicines Inc
RVMD
10
14
1
0
0
25
Kymera Therapeutics Inc
KYMR
9
13
2
0
0
24
CRISPR Therapeutics AG
CRSP
4
8
11
0
0
23
Tempus AI Inc
TEM
4
7
11
0
1
23
Biontech SE
BNTX
4
11
8
0
0
23
IQVIA Holdings Inc
IQV
8
12
3
0
0
23
Financial Forecasting
Based on analysts' estimates, VIR EPS is projected to reach -0.754 in FY2026Q3, following reported EPS of 0.477 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.49
-0.10
0.33
-0.75
-0.67
Actual
-0.31
-0.85
0.48
--
--
Surprise
+37.28%
-794.13%
+43.38%
--
--
FAQs
What is Vir Biotechnology Inc's expected revenue for the next quarter?
Vir Biotechnology Inc's expected revenue is 127.50K.
What is Vir Biotechnology Inc's price target?
Analysts forecast that Vir Biotechnology Inc's price target is USD 21.00, with the highest forecast at USD 30.00 and the lowest forecast at USD 15.00.
How have Vir Biotechnology IncVIR's recent earnings per share performed?
The market expectation was USD 0.48, while Vir Biotechnology IncVIR's earnings per share (EPS) for the previous quarter was USD -0.85. EPS for the next quarter is expected at USD -0.75.
What is the analyst rating for Vir Biotechnology Inc?
Based on the ratings of Vir Biotechnology Inc's stock from 9 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.